

**Subject:** Medical Science Liaison (MSL) Notes - Critical Discussion on ImmunoViva

**Date:** January 12, 2025

**Provider:** Dr. Jason Williams

**Title:** Rheumatologist

**Institution:** JointCare Rheumatology Clinic

**Summary of Key Discussion Points:**

**1. Introduction:**

- Introduced ImmunoViva as an immunomodulatory therapy designed to enhance immune responses.
- Dr. Williams expressed skepticism, questioning the necessity for a new immunomodulator in an already complex landscape.

**2. Provider's Current Patient Cases:**

- Dr. Williams shared reservations about the practical impact of ImmunoViva in patients with rheumatic diseases.
- Discussed specific cases where traditional disease-modifying antirheumatic drugs (DMARDs) have shown established efficacy.

**3. Efficacy and Clinical Data:**

- Presented recent clinical data showcasing ImmunoViva's modulation of immune responses.
- Dr. Williams questioned the clinical significance of the reported reductions in autoimmune flare-ups and sought comparative data.

**4. Safety Profile:**

- Discussed the reported safety profile of ImmunoViva, with minimal reported immunosuppressive effects.
- Dr. Williams expressed concerns about the lack of long-term safety data and potential unforeseen immunological consequences.

**5. Mechanism of Action:**

- Explained ImmunoViva's mechanism, focusing on its selective modulation of immune checkpoints and cytokine balance.
- Dr. Williams questioned the necessity for such selective modulation and inquired about potential off-target effects.

**6. Patient Adherence and Education:**

- Discussed strategies for enhancing patient adherence through a subcutaneous injection every two weeks.

- Dr. Williams expressed skepticism about patient compliance, citing the frequency of injections as a potential barrier.

**7. Emerging Research and Future Developments:**

- Highlighted ongoing research on ImmunoViva's potential in other autoimmune conditions.
- Dr. Williams questioned the need for expanding research without addressing existing concerns about clinical relevance.

**8. Competitive Landscape:**

- Compared ImmunoViva to existing DMARDs and biologics, questioning the added benefits of its selective modulation.
- Discussed challenges of introducing a new drug without clear advantages over established treatments.

**9. Access and Reimbursement:**

- Provided updates on access and reimbursement programs for rheumatology clinics.
- Dr. Williams expressed reservations about the cost-effectiveness of ImmunoViva compared to existing treatments.

**10. Action Items and Follow-Up:**

- Dr. Williams did not express interest in further collaboration or follow-up.
- Agreed to remain open to future data but expressed skepticism about the drug's practical impact in rheumatology.

**11. Closing Remarks:**

- Acknowledged Dr. Williams's concerns and thanked him for his candid feedback.
- Expressed understanding and committed to addressing ongoing questions or concerns as the drug's development progresses.